期刊文献+

氢氯吡格雷与双嘧达莫预防自体大隐静脉移植内瘘失功的有效性和安全性比较 被引量:6

Comparison of clopidogre and dipyridamole for preventing dysfunction of the autologous fistula by great saphenous venous transposition
下载PDF
导出
摘要 目的比较氢氯吡格雷和双嘧达莫对预防自体大隐静脉移植内瘘失功的临床疗效及安全性。方法前瞻性纳入2009年1月至2012年05月期间行自体大隐静脉移植内瘘的患者,术后随机分为氢氯吡格雷治疗组(A组),双嘧达莫治疗组(B组),于治疗后3个月及6个月观察移植静脉内瘘的通畅率、狭窄率、动脉吻合口内径、静脉吻合口内径、动脉段内径(距动脉吻合口3cm)及静脉段内径(距静脉吻合口3cm)等指标,以及药物并发症和不良反应。使用SPSS17.0软件进行统计分析。结果共纳入病例30例,其中A组16例,B组14例。A组治疗3个月、6个月的通畅率均较B组的高,狭窄率均较B组的低。其中A组治疗6个月的通畅率(81.25%)较B组(35.71%)的差异有显著性(=6.451,P=0.024),A组治疗3个月动脉吻合口、静脉吻合口内径较B组略大,但差异无显著性(P>0.05),相应时段移植静脉动脉段内径(距动脉吻合口3cm)及静脉段内径(距静脉吻合口3cm)差异无显著性;A组治疗6个月动脉吻合口、静脉吻合口内径较B组大,差异有显著性(t值分别为2.142,2.132,P值分别为0.041、0.042),相应时段移植静脉动脉段内径(距动脉吻合口3cm)及静脉段内径(距静脉吻合口3cm)略大,但差异无显著性。两组均未出现严重不良反应。结论氢氯吡格雷预防自体大隐静脉移植内瘘狭窄及血栓形成的效果优于双嘧达莫,无明显不良反应,具有广阔的应用前景。 Objective To compare the efficacy and safety of clopidogre and dipyridamole for the prevention of autologous great saphenous venous transposition fistula dysfunction. Methods We prospec- tively recruited patients who received the operation of autologous great saphenous venous transposition fistula. After the surgery, patients were randomly assigned into either clopidogre group (group A) or dipy- ridamole group (group B). At the 3rd and 6th months after the enrollment, fistula patency, stenosis rate, arterial anastomotic diameter, venous anastomotic diameter, diameters of the arterial/venous graft segments (3cm from arterial/venous anastomotic sites), complications, and adverse events were recorded. Data were analyzed by using SPSS 17.0 software. Results We observed 30 patients, of which 16 were in group A, and 14 were in group B. At the time points of 3rd and 6th months, group Ahad a higher fistula patency rate and a lower stenosis rate than group B. At the 6th month, fistula patency was statistically significant between the two groups (Z~=6. 451, /)=0.024). Arterial and venous anastomotic diameters were slight wider in group A than in group B but without statistical significance (P 〉 0.05) at the 3rd month, and were significant larger in group Athan in group B (t=-2. 142 and 2. 132, P=-0.041 and 0.042, respectively) at the 6th month. Diameters of the arterial/venous graft segments were similar between the two groups at 3rd and 6th months. No severe adverse effects were reported in either of the two groups. Conclusions Clopidogre is superior to dipyridamole in the prevention of thrombosis and stenosis in autologous great saphenous venous transposi- tion fistula without notable adverse effects. As an anti-platelet therapy for fistula preservation, clopidogre shows better effects for clinical use.
出处 《中国血液净化》 2013年第6期301-304,共4页 Chinese Journal of Blood Purification
关键词 大隐静脉 内瘘 失功 氢氯吡格雷 双嘧达莫 Great saphenous vein Fistula Dysfunction Clopidogre Dipyridamole
  • 相关文献

参考文献12

  • 1Gilpin V,Nichols WK. Vascular access for hemodialysis: thrills and thrombosis[J]. J Vasc Nurs, 2010, 28:78-83.
  • 2Anand S, Kurella Tamura M, Chertow GM. The elderly patients on hemodialysis[J]. Minerva Urol Nephrol, 2010, 62:87- 10l.
  • 3Khan UA, Krishnamoorthy B,Najam O,et al. A comparative analysis of saphenous vein conduit harvesting techniques for coronary artery bypass grafting-standard bridging versus the open technique[J]. Interact Cardiovasc Thorac Surg, 2010, 10:27-31.
  • 4Oto T. Endoscopic saphenous vein harvesting for hemodi?alysis vascular access creation in the forearm: A new approach for arteriovenous bridge graft[J]. J Vasc Access, 2003, 4:98-1Ol.
  • 5Fahrtash F,Kairaitis L,Gruenewald S,et al.Defining a significant stenosis in an autologous radio-cephalic ar?teriovenous fistula for hemodialysis[J].Semin Dial,20ll, 24: 231-238.
  • 6Lin PH,Bush RL,Nguyen L,et al. Anastomotic strategies to improve hemodialysis access patency-a review[J]. Vasc Endovascular Surg,2005,39:l35-42.
  • 7Alexopoulos D,Xanthopoulou T,Panagiotou A,et al.Preva?lence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis[J].Am J Kidney Dis,20l2, 59: 469-4 7l.
  • 8Ghorbani A, Aalamshah M, Shahbazian H,et al. Randomized controlled trial of clopidogrel to prevent primary arte?riovenous fistula failure in hemodialysis patients[J]. Indian J Nephrol,2009, 19:57-61.
  • 9Jackson RS, Sidawy AN, Amdur RL, et al. Angiotensin recep?tor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialy?sis access placement[J].J Vasc Surg, 2011,54: 1706-1712.
  • 10廖纯兴,潘巧玲,杨建泉,朱德霞,张军.氯吡格雷在长期中心静脉导管功能不良中的应用[J].中国临床药理学与治疗学,2012,17(6):687-690. 被引量:6

二级参考文献18

  • 1叶朝阳,付文成,戎殳,陈静,马晓红,张斌,梅长林.长期深静脉留置双腔导管血液透析的临床应用[J].肾脏病与透析肾移植杂志,2004,13(3):231-234. 被引量:122
  • 2韦洮,张大伟,赵青艺,檀敏,蔡美顺,杨洪杰,于仲元.维持性血液透析患者血管通路血流量递减与Kt/V及尿素清除率定量分析[J].中国血液净化,2005,4(1):14-15. 被引量:27
  • 3黎磊石,刘志红主编.中国肾脏病学[M].北京:人民军医出版社,2008,1328-1338
  • 4Yevzlin AS, Song GU, Sanchez RJ, et al. Fluoroscopically guided vs modified traditional placement of tunneled hemodialysis catheters: clinical out- comes and cost analysis[J]. J Vasc Access, 2007, 8 (4) :245-251.
  • 5No authors listed. NKF-K/DOQI Cliniea practice guidelines for vascular access: up-date 2000 [J]. Am J Kidney Dis, 2001,37 (1 Suppl 1) : 137-181.
  • 6Alexopoulos D, Xanthopoulou I, Panagiotou A, et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis [J]. Am J Kidney Dis, 2012, 59(3):469-471.
  • 7Ghorbani A, Aalamshah M, Shahbazian H, et al. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients[J]. Indian J Nephrol, 2009, 19 (2): 57 - 61.
  • 8Jackson RS, Sidawy AN, Amdur RL, et al. Angiotensin receptor blockers and antiplatelet agents are associated with improved primary patency after arteriovenous hemodialysis access plaeement[J]. J Vasc Surg, 2011, 54 (6):1706-1712.
  • 9National Kidney Foundation. K-DOQI clinical practice guidelines forvascular access: Update 2000[J].Am J Kidney ESs, 2001?37 (Suppl1):137-181.
  • 10Lin PH,Bush RI-,Nguyen h,etal. Anastomotic strategies to improvehemodialysis access patency: A review[J].Vase Endovascular Surg,2005,39(2):135.

共引文献13

同被引文献46

  • 1王华亭,蔡生业,姚成芳,朱宗涛,王丽.复方花刺参黏多糖对球囊血管成形术兔血浆内皮素及血清一氧化氮的影响[J].中国海洋药物,2004,23(5):6-10. 被引量:5
  • 2张磊,吴河水,陈燕,陈铭坤,王琳,郭兴军,王春友,张景辉.一氧化氮对急性出血坏死性胰腺炎肝脏中Toll样受体2/4 mRNA表达的影响[J].中国危重病急救医学,2006,18(3):161-164. 被引量:5
  • 3[6]王海燕,王梅主译.慢性肾脏病及透析的临床实践指南[M].北京:人民卫生出版社,2005:256-257
  • 4Andrassy K, Malluche H, Bomefeld H. Prevention of p. o. clot- ting spective double study. Klim Wochenschr, 1974, 52.. 348- 349.
  • 5Kooistra MP, Van EsA, et al. Low-dose aspirin does not pre- vent thrombovascular accidents in low-risk heamodiaiysis pa- tients during treatment with recombinant human erythropoie- tin. Nephrol Dial Transplant, 1994,9 : 1115-1120.
  • 6Grontoft KC, Larsson R, Mulec H, et al. Effects of tielopidine in AV-fistula surgery in uremia. Stand J Urol Nephrol, 1998, 32 : 276-283.
  • 7Gilpin V,Nichols WK.Vascular access for hemodialysis:Thrills and thrombosis.J Vasc Nurs,2010,28:78-83.
  • 8Anand S,Kurella TM,Chertow GM.The elderly patients on hemodialysis.Minerva Urol Nephrol,2010,62:87-101.
  • 9Ⅲ NKF K/DOQI Clinical Practice Guidelines for Voscular Access:Update 2000.AJKD,2001,37:137-181.
  • 10National Kidney Foundation.KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates:Hemodialysis Adequacy,Peritoneal Dialysis Adequacy and Vascular Access.Am J Kidney Dis,2006,48:1-322.

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部